Product Images Guanfacine

This text provides information about Guanfacine Extended-Release Tablets, each containing 1 mg of guanfacine. It includes details about storage conditions, dosage instructions, and a link to the package insert for complete prescribing information. The tablets should not be crushed, chewed, or broken before swallowing. The product is distributed by Advagen Pharma Ltd. in East Windsor, NJ, USA, and manufactured by Rubicon Research Pwi. Ltd. in Thane, India. The package contains 1000 tablets. For more details, the package insert is available at the provided website.*

Each tablet contains 1 mg of guanfacine hydrochloride USP for extended release. Manufactured by Rubicon Research Ltd., in Thane, India, these tablets are distributed by Advagen Pharma Ltd. in East Windsor, NJ, USA. Store between 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). Dispense in a tight container and do not crush, chew, or break the tablets before swallowing. More information can be found on the Patient Information Sheet and Package Insert available at the provided website.*

Each tablet contains 1mg of guanfacine hydrochloride USP, manufactured by Rubicon Research Pvt. Ltd. The tablets should be stored at 20°C to 25°C (68°F to 77°F), with excursions permitted to 15°C to 30°C (59°F to 86°F). The usual dosage can be found in the package insert, and the extended-release tablets should not be crushed, chewed, or broken before swallowing. For more information, visit the website of Advagen Pharma Ltd. at the provided link.*

This text provides information on guanfacine tablets containing 1 mg of guanfacine hydrochloride USP. It includes the usual dosage instructions, storage conditions, and a caution not to crush, chew, or break the tablets before swallowing. The tablets are to be dispensed in a tight container. Additional details, such as manufacturing and distribution information, are also included along with a link to the package insert.*

This text provides information about guanfacine extended-release tablets containing 2 mg of guanfacine hydrochloride USP. It includes details on dosage, storage conditions, precautions, and where to find the package insert for complete prescribing information. The tablets should not be crushed, chewed, or broken before swallowing. It also lists the distributor and manufacturer details. For more details, visit the provided link.*

This is a medication label for tablets containing guanfacine hydrochloride USP, each tablet having 2 mg of guanfacine. The tablets are distributed by Advagen Pharma Ltd. and manufactured by Rubicon Research Ltd. The usual dosage and storage instructions are provided on the label. It is recommended to dispense the tablets in a tight container and to not crush, chew, or break them before swallowing. Additionally, the patient information sheet and package insert are available online.*

Each tablet contains 2mg of guanfacine hydrochloride USP. The tablets should be stored at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). These extended-release tablets are manufactured by Rubicon Research Pvt Ltd. It is recommended not to crush, chew, or break the tablets before swallowing. This product is distributed by Advagen Pharma Ltd., situated in East Windsor, NJ, USA. For complete prescribing information, refer to the package insert.*

Each tablet of guanfacine hydrochloride USP contains 2 mg of guanfacine. The usual dosage guidelines can be found in the package insert available at the given website. Storage should be done at a temperature between 20°C to 25°C (68°F to 77°F) with short excursions permitted. These extended-release tablets should not be crushed, chewed, or broken before swallowing. The package includes 500 tablets and is distributed by Advagen Pharma Ltd. it is manufactured by Rubicon Research Pvt. Ltd. in India. Make sure to follow the prescription guidelines for effective use of this medication.*

This is a medication information for Guanfacine Extended-Release Tablets, USP, which contain 3 mg of guanfacine hydrochloride. The usual dosage information can be found in the package insert, but typically they are stored at 20-25°C and dispensed in a tight container. It is important not to crush, chew, or break the tablets before swallowing. The tablets are distributed by Advagen Pharma Ltd. in the USA and manufactured by Rubicon Research Pvt. Ltd. in India. The package insert can be accessed online for further details.*

Each tablet contains 3 mg of guanfacine hydrochloride, distributed by Advagen Pharma Ltd. in East Windsor, NJ, USA. The usual dosage and prescribing information can be found in the package insert manufactured by Rubicon Research Ltd. in Thane, India. The tablets should be stored at 20°C to 25°C and not crushed or chewed before swallowing. Dispense in a tight container. For more information, the Patient Information Sheet and Package Insert can be found at the provided link.*

Each tablet contains 3mg of guanfacine hydrochloride USP. The tablets should be stored at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). They are distributed by Advagen Pharma Ltd. in East Windsor, NJ. The usual dosage and prescribing information can be found in the package insert. These are extended-release tablets and should not be crushed, chewed, or broken before swallowing. The tablets are manufactured by Rubicon Research Pvt. Ltd. and dispensed in a tight container. Rev.01, 09/24 Tablets, USP.*

Each tablet of Guanfacine Extended-Release Tablets, USP, contains 3 mg of guanfacine hydrochloride. The usual dosage information can be found in the package insert available at the provided link. It is recommended to store the tablets at room temperature and in a tight container. Avoid crushing, chewing, or breaking the tablets before swallowing. This medication is distributed by Advagen Pharma Ltd. in the USA and manufactured by Rubicon Research Pvt. Ltd. in India.*

Each tablet contains 4 mg of guanfacine as guanfacine hydrochloride USP. The usual dosage is available in the package insert. The tablets should not be crushed, chewed, or broken before swallowing. Store the product at 20°C to 25°C with permissible excursions to 15°C to 30°C. The package contains 1000 tablets for extended-release of Guanfacine. This medication is distributed by Advagen Pharma Ltd. in East Windsor, NJ, USA, and manufactured by Rubicon Research Pwt. Ltd. in Thane, India. More information can be found in the package insert available at the provided link.*

This text provides information about Guanfacine Extended-Release Tablets, USP, containing 4 mg of guanfacine hydrochloride. It includes details on dosage, storage instructions, and a reminder not to crush or chew the tablets. The manufacturer is Rubicon Research Ltd. in India, distributed by Advagen Pharma Ltd. in East Windsor, USA. The National Drug Code (NDC) is 72888-227-01. Furthermore, it directs to an online resource for the Patient Information Sheet and Package Insert.*

Each tablet contains 4 mg of guanfacine hydrochloride USP. These extended-release tablets should be stored at 20°C to 25°C (68°F to 77°F), with excursions permitted to 15°C to 30°C (59°F to 86°F). The usual dosage guidelines can be found in the package insert. It is essential not to crush, chew, or break the tablets before swallowing. For more detailed prescribing information, visit https//www.advagenpharma.com/pil/.*

This text provides information about a medication containing 4 mg of guanfacine hydrochloride in tablet form. The tablets are extended-release and should be stored at a temperature range of 20°C to 25°C. It is recommended not to crush, chew, or break the tablets before swallowing. The medication is distributed by Advagen Pharma Ltd. and manufactured by Rubicon Research Pvt. Ltd. in India. Additional details can be found at the provided website.*

This text provides information on interacting drugs, specifically Oral Methylphenidate and Lisdexamfetamine Dimesylate. It includes pharmacokinetic parameters such as Cmax (maximum concentration) and AUC (area under the curve), along with fold change and 90% confidence intervals. The data suggests changes relative to a reference point for the specified drugs.*